- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02597075
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
While safety and feasibility as well as some improvements in fitness, fatigue and certain aspects of quality of life have been shown for physical activity in cancer patients during treatment, none of the pre-requisites above (i-iv) is fulfilled in the setting of patients with advanced colon cancer.
However, evidence, primarily from the adjuvant setting, that physical activity impacts on treatment tolerability and tumor progression is a strong enough rationale to now embark on this prospective trial. By assessing in a large randomized controlled trial whether a 12-week structured physical activity program during chemotherapy in patients with newly diagnosed colorectal cancer undergoing standard first-line chemotherapy improves progression-free survival as compared to standard first-line chemotherapy alone, all pre-requisites for a practice-changing intervention are met.
The physical exercise ACTIVE-program describes a 12-week exercise program consisting of a combination of a bi-weekly aerobic exercise (cycle ergometer) supervised by a physical therapist and a self-paced increase in physical activity during daily life using a pedometer with a daily step goal as a motivational tool.
In addition to the supervised exercise program twice a week, patients of the intervention group are recommended to be physically active at home.
All patients will undergo standard systemic therapy for metastatic colorectal cancer. Patients in the care-as-usual group are not actively encouraged to change their physical activity level e.g. to start a fitness program during chemotherapy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Salzburg, Austria, r.greil@salk.at
- Universitätsklinikum der PMU Salzburg
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen GmbH
-
-
-
-
-
Aarau, Switzerland, CH-5001
- Kantonsspital Aarau
-
Aarau, Switzerland, CH-5000
- Tumor Zentrum Aarau
-
Baden, Switzerland, 5404
- Kantonsspital Baden
-
Basel, Switzerland, CH-4016
- St. Claraspital
-
Basel, Switzerland, CH-4031
- Clinical Cancer Research Center at University Hospital Basel
-
Bellinzona, Switzerland, CH-6500
- Istituto Oncologico della Svizzera Italiana IOSI
-
Biel, Switzerland, CH-2501
- Spitalzentrum Biel
-
Brig, Switzerland, 3900
- Spitalzentrum Oberwallis
-
Chur, Switzerland, 7000
- Kantonsspital Graubünden
-
Fribourg, Switzerland, CH-1708
- Hopital Fribourgeois HFR
-
Genève 14, Switzerland, CH-1211
- Hôpitaux universitaires de Genève
-
Lausanne, Switzerland, CH-1004
- Centre de Chimiothérapie Anti-Cancéreuse
-
Liestal, Switzerland, CH-4410
- Kantonsspital Baselland
-
Luzern, Switzerland, 6000
- Kantonsspital Luzern
-
Münsterlingen, Switzerland, CH-8596
- Spital Thurgau
-
Olten, Switzerland, CH-4600
- Kantonsspital Olten
-
St. Gallen, Switzerland, CH-9007
- Kantonsspital - St. Gallen
-
Thun, Switzerland, 3600
- SpitalSTS AG Simmental-Thun-Saanenland
-
Zurich, Switzerland, CH-8091
- Universitatsspital Zurich
-
Zurich, Switzerland, 8002
- Onkozentrum - Klinik im Park
-
Zürich, Switzerland, CH-8032
- Onkozentrum Hirslanden Zürich
-
Zürich, Switzerland, CH-8063
- Stadtspital Triemli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent according to ICH/GCP regulations before randomization.
- Patient with histologically or cytologically confirmed colorectal carcinoma (CRC) who start palliative first-line systemic therapy for inoperable or metastatic disease.
Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment.
- Patients with histologically or cytologically confirmed colorectal carcinoma (CRC), who start first-line "conversion"-therapy for borderline resectable metastatic disease and will be reassessed for metastasectomy after 3-4 months of systemic treatment.
Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment.
Patients who are diagnosed with metastatic disease and were initially treated with surgery and/or radiochemotherapy to the primary tumor are eligible (except if all disease sites/metastases have been removed) Patients who have been curatively treated with histologically or cytologically confirmed nonmetastatic CRC previously and now relapse with metastatic disease are also eligible, irrespective of previous radiochemotherapy and/or adjuvant chemotherapy
- Patients must have measurable disease on CT scan or MRI to be performed within 6 weeks before randomization (measurability criteria according to RECIST 1.1, non-nodal lesions ≥10 mm, lymph nodes ≥15mm) OR evaluable disease i.e. patient with nonmeasurable metastases but elevated serum tumor-marker (CEA at least >2xULN).
- Command of written and spoken language allowing for informed consent and for filling in trial questionnaires.
- Baseline patient-reported outcomes (PROs) have been completed.
- WHO performance status 0-2.
- Age ≥18 years
Exclusion Criteria:
- Pre-existing severe medical conditions precluding participation in a physical activity program as determined by the local investigator. Such conditions include: chronic heart failure (greater than NYHA II), recent myocardial infarction (less than 3 months ago), unstable angina pectoris, clinically significant arrhythmias, uncontrolled hypertension with repeated systolic blood pressure above 160mmHg, and COPD (requiring oxygen supply or GOLD stadium greater than 2).
- Inability to ride a cycle ergometer e.g. for musculoskeletal reasons.
- Patients in whom all CRC metastases have been removed surgically. It is allowed to include patients for whom metastasectomy might be an option if chemotherapy induces a significant response.
- Any serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes).
- Concurrent treatment in a trial with experimental drugs or other anti-cancer therapy, which are hypothesized to alter tumor progression. Participation in an observational trial or a translational trial is allowed. Palliative radiotherapy is allowed.
- Psychiatric disorder precluding understanding of trial information, giving informed consent, filling out PRO forms, or interfering with compliance.
- Any psychological, familial, sociological or geographical condition potentially hampering proper compliance with the trial protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A: with ST + PA
Standard therapy + structured Physical activity and pedometer
|
|
Active Comparator: Arm B:
Standard therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: every 8 or 9 weeks during one year
|
Change between 2 tumor assessments
|
every 8 or 9 weeks during one year
|
Change in Patient-reported symptoms as measured by ESAS-r
Time Frame: in at week 6, 12, 18, 24, 48
|
The ESAS-r is a summary score ranging from 0 to 100 with lower scores representing better quality of life of the patients.
|
in at week 6, 12, 18, 24, 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: after progression (expected 1 year) lifelong follow-up
|
time from randomization to date of death.
Patients without event at the time of analysis will be censored at the date they were last known to be alive.
|
after progression (expected 1 year) lifelong follow-up
|
Best Objective Response
Time Frame: at week 8 or 9 during one year
|
best tumor response achieved during first-line systemic therapy according to RECIST criteria.
Only remission status achieved during first-line therapy will be considered.
|
at week 8 or 9 during one year
|
Selected adverse events
Time Frame: day 1 of each cycle (every 8 or 9 weeks)
|
assessed according to NCI CTCAE v4.0.
|
day 1 of each cycle (every 8 or 9 weeks)
|
Chemotherapy-completion-rate
Time Frame: week 6, 12, 18, and 24
|
total dose in mg which was applied divided by the total dose in mg which was initially planned according to the planned chemotherapy scheme. Absolute doses of chemotherapy agents applied will be collected after each chemotherapy cycle. The total planned dose will be derived based on the planned chemotherapy scheme which is specified at baseline incorporating weight or body surface. The chemotherapy-completion-rate is defined as the number of dose modifications due to toxicity during the first 24 weeks after randomization per patient: after each 6 week-period (week 6, 12, 18, and 24) it is assessed whether there have been dose modifications (decrease/delay of systemic treatment i.e. chemo or biological) due to toxicity during the previous 6 weeks (y/n). The proportion of patients without any dose modification due to toxicity during the first 24 weeks will be calculated as well |
week 6, 12, 18, and 24
|
Initiation or increase of anti-hypertensive drugs
Time Frame: day 1 of each cycle (every 8 or 9 weeks) for one year
|
In the subgroup of patients who receive bevacizumab.
The proportion of patients receiving new or increased doses of anti-hypertensive drugs will be calculated.
|
day 1 of each cycle (every 8 or 9 weeks) for one year
|
Collaborators and Investigators
Investigators
- Study Chair: Viviane Hess, Prof Dr med, University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAKK 41/14 - ACTIVE-2
- 2015-003733-10 (Other Identifier: SNCTP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on standard therapy + physical activity program
-
University of South CarolinaPrisma Health-MidlandsCompleted
-
McMaster UniversityUniversity of Alberta; Macquarie University, Australia; Universidade Federal...CompletedLow Back Pain | Low Back Pain, RecurrentCanada
-
University of CadizCompletedChronic Nonspecific Low Back PainSpain
-
Universidad Santo TomasEmory University; Universidad Pública de Navarra; Universidad de Granada; University... and other collaboratorsCompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
University Hospital, Clermont-FerrandRecruiting
-
Lawson Health Research InstituteCompleted
-
Case Western Reserve UniversityNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
University of ValenciaGeneralitat ValencianaRecruiting
-
Universidade da CoruñaCompleted